Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2025-12-25 @ 2:17 AM
NCT ID:
NCT03772834
Eligibility Criteria:
Inclusion Criteria:
* Have a diagnosis of prostate cancer and be scheduled to receive radiotherapy with concurrent androgen deprivation therapy, and presence of fatigue with severity of 1/10, on a 0-10 scale for at least 2 weeks
* Patient not regularly engaging in moderate aerobic exercise for \>90 minutes/week and/or vigorous aerobic exercise for \>30 minutes/week, and/ or strength training for \>/= 1 day/week
* Have no clinical evidence of cognitive failure as evidenced by Memorial Delirium Assessment Scale score of \</=13 at baseline
* Be aged 18 years or older
* Be willing to engage in follow-up telephone calls with a research staff
* Be willing to participate in the exercise programs
* Have telephone access so they can be contacted by the research staff
* Have a hemoglobin level of \>/= 10 g/dL within 2 weeks of enrollment
* Be able to understand the description of the study and give written informed consent
* Have a Zubrod performance status score of 0 to 2
* Seen at an outpatient clinic at MD Anderson Cancer Center, its Houston Area Locations (HALs) or Smith Radiation Oncology Clinic (HHS)
Exclusion Criteria:
* Have a major contraindication to MethylphenidateMP) (e.g., allergy/hypersensitivity to study medications or their constituents), exercise (e.g., cardiac disease), or conditions making adherence difficult as determined by the attending physician
* Be currently taking MP, or have taken it within the previous 10 days
* Be unable to complete the baseline assessment forms (e.g., due to language or sensory barriers) or to understand the recommendations for participation in the study
* Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine
* Have glaucoma
* Have severe cardiac disease (New York Heart Association functional class III or IV)
* Have tachycardia and/or uncontrolled hypertension
* Be currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantone, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine).
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Study:
NCT03772834
Study Brief:
Protocol Section:
NCT03772834